Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a quick Beta-Blocker shot save more heart muscle?

NCT ID NCT07293832

Knowledge-focused Sponsor: Aristotle University Of Thessaloniki Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether giving the beta-blocker landiolol early, during a heart attack, can reduce the amount of heart muscle that dies. It will follow 100 patients who get either landiolol or a standard oral beta-blocker, based on their doctor's choice. The main goal is to measure heart damage with an MRI three months later.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
landiolol (a cardio-selective beta-blocker)
What this could lead to
If results are promising, it could suggest that early landiolol use helps limit heart muscle damage after a heart attack.
What could go wrong
This is an observational study, not a randomized trial, so results may be influenced by patient differences. The study is small (100 people) and early, so findings may not be conclusive.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2024

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

All patients diagnosed with STEMI presenting to Hippokration General Hospital of Thessaloniki will be evaluated for eligibility.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age between 18 and 80 years * Patients with electrocardiogram showing ST-segment elevation ≥2 mm in 2 or more contiguous leads for more than 30 minutes * Estimated time from symptom onset to reperfusion ≤12 hours * Patients scheduled to undergo primary angioplasty * Patients who have signed a consent form Exclusion Criteria: * Patients receiving chronic medication with beta-adrenergic blockers * Patients with a previous myocardial infarction * Persistent systolic blood pressure \<90 mmHg * Persistent heart rate \<55 beats per minute * Patients with Killip class III (acute pulmonary edema) or IV (cardiogenic shock) on initial examination * 12-lead electrocardiogram with PR interval \>200 milliseconds * 12-lead electrocardiogram showing second- or third-degree atrioventricular block * Bronchospasm requiring bronchodilator treatment * Possible pregnancy or postpartum period * Inability or refusal to sign the consent form

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STEMI are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ST-elevation myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

STEMI

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hippokration General Hospital of Thessaloniki

    RECRUITING

    Thessaloniki, Thessaloniki, 546 42, Greece

More trials for these conditions

Other studies related to the condition(s) this trial covers.